Belsar-M 5 mg+20 mg (Tablet)
Unit Price: ৳ 12.00 (4 x 7: ৳ 336.00)
Strip Price: ৳ 84.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Amlodipine besilate olmesartan medoxomil |
| Company | Beacon pharmaceuticals plc |
| Also available as |
Indications
- Treatment of hypertension alone or with other antihypertensive agents
- Lowering blood pressure
- Initial therapy in patients likely to need multiple antihypertensive agents
- Individualized therapy based on baseline blood pressure and target goal
Pharmacology
- Amlodipine as a dihydropyridine calcium channel blocker
- Amlodipine's effect on vascular smooth muscle cells and cardiac muscle cells
- Peripheral arterial vasodilator effect of Amlodipine
- Angiotensin II as a potent vasoconstrictor and the primary vasoactive hormone
- Olmesartan Medoxomil blocking vasoconstrictor and aldosterone-secreting effects of angiotensin II
- Reversible competitive inhibitor of the AT1 receptor by Olmesartan Medoxomil
Dosage & Administration
- Start with 5/20 mg once daily for 1 to 2 weeks
- Titrate as needed up to a maximum of 10/40 mg once daily
- Recommended starting dose of Amlodipine is 2.5 mg in patients 75 years and older
- Not recommended to initiate therapy with this combination drug in patients over 75 years old
Interaction
- Attenuation of antihypertensive effect by NSAIDs including selective COX-2 inhibitors
- Close monitoring of blood pressure, renal function, and electrolytes in patients on combination therapy
Contraindications
- Contraindicated with Aliskiren in patients with diabetes
Side Effects
- Common side effects include peripheral edema, headache, flushing, and dizziness
- Potential for causing sprue-like enteropathy
Pregnancy & Lactation
- Pregnancy Category D
- Not recommended for use in 2nd and 3rd trimester of pregnancy due to risk of fetal death
- Unknown excretion of Olmesartan and Amlodipine in human milk
Precautions & Warnings
- Caution in volume- or salt-depleted patients for risk of hypotension
- Caution in patients with severe aortic stenosis for risk of vasodilation
- Caution in patients with severe obstructive coronary artery disease for risk of increased frequency, duration, or severity of angina or acute MI
Use in Special Populations
- Safety and effectiveness not established in pediatric patients
- No overall differences in safety or effectiveness observed between subjects 65 years of age or older and younger subjects
- No studies in patients with renal impairment
- Not recommended for initial therapy in hepatically impaired patients
Overdose Effects
- No information on overdose in humans
Therapeutic Class
- Combined antihypertensive preparations
Storage Conditions
- Do not store above 30°C
- Keep away from light and out of the reach of children